Researchers review progress of treating glutamate signalling in depression
Friday, March 17, 2017 - 14:01
in Health & Medicine
Major depressive disorder (MDD) impacts 15 million Americans and is the leading cause of disability, yet current treatments possess limited efficacy. Ketamine, which has been repurposed as a rapidly acting antidepressant, has emerged as an experimental and potentially promising compound to treat severe depression through a novel drug action mechanism that blocks glutamate receptors.